IP Library Granted Patent US 8,541,205
Granted Patent B2
US 8,541,205 · App. 13/461,170 · Granted Sep 24, 2013

Variant forms of urate oxidase and use thereof

Inventors: Jacob Hartman (Holon, IL); Simona Mendelovitz (Ramat Aviv, IL)
Assignee: Savient Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,205
App. No.
13/461,170
Granted
Sep 24, 2013
Kind
B2
Abstract

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.

Claims (14)

1. An isolated nucleic acid comprising a nucleic acid sequence which encodes (a) a uricase comprising a mammalian uricase amino acid sequence truncated at the amino terminus or the carboxy terminus or both the amino and carboxy termini by 1-6 amino acids and further comprising an amino acid substitution with threonine at position 7 (D7T), an amino acid substitution at position 46 (S46T), an amino acid substitution with lysine at position 291 (R291K) and an amino acid substitution with serine at position 301 (T301S), said truncation and amino acid substitution being relative to a naturally occurring pig uricase having an amino acid sequence of SEQ ID NO:11;

(b) the uricase of (a) further comprising an amino terminal amino acid, wherein the amino terminal amino acid is alanine, glycine, proline, serine, or threonine;

(c) the uricase of (b) wherein the amino terminal amino acid is threonine;

(d) the uricase of (a) consisting of the amino acid sequence of SEQ ID NO. 8;

(e) the uricase of (a) wherein the N-terminal amino acid is methionine; or

(f) the uricase of (e) comprising the amino acid sequence of SEQ ID NO. 7.

2. The isolated nucleic acid of claim 1 , wherein the nucleic acid sequence is operatively linked to a heterologous promoter.

3. The nucleic acid of claim 2 , wherein the promoter is the osmB promoter.

4. A nucleic acid vector comprising the nucleic acid of claim 2 .

5. A host cell comprising the vector of claim 4 .

6. An isolated nucleic acid comprising a nucleic acid sequence encoding a uricase comprising the amino acid sequence of SEQ ID NO. 7 or SEQ ID NO. 8.

7. The isolated nucleic acid of claim 6 , wherein the nucleic acid sequence comprises SEQ ID NO. 9 or SEQ ID NO. 10.

8. The isolated nucleic acid of claim 6 , wherein the nucleic acid sequence is operatively linked to a heterologous promoter.

9. The nucleic acid of claim 8 , wherein the promoter is the osmB promoter.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 065178/0965 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SELLER'S NAME AND EXECUTION DATE PREVIOUSLY RECORDED ON REEL 032675 FRAME 0936. ASSIGNOR(S) HEREBY CONFIRMS THE SELLER'S NAME SHOULD READ SAVIENT PHARMA HOLDINGS, INC. AND THE EXECUTION DATE FOR BOTH PARTIES SHOULD READ 01/09/2014. Recorded Jun 16, 2023
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, INC.
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 064009/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2023
From: HARTMAN, JACOB; MENDELOVITZ, SIMONA
To: SAVIENT PHARMACEUTICALS, INC.
Reel/Frame 062279/0512 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 061805 FRAME 0076. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 1, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC.
Reel/Frame 062073/0930 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2022
From: HORIZON PHARMA RHEUMATOLOGY LLC
To: HORIZON THERAPEUTICS USA, INC
Reel/Frame 061805/0076 →
CHANGE OF NAME Recorded Nov 18, 2016
From: HORIZON PHARMA USA RHEUMATOLOGY LLC
To: HORIZON PHARMA RHEUMATOLOGY LLC
Reel/Frame 040648/0367 →
CHANGE OF NAME Recorded Nov 18, 2016
From: CREALTA PHARMACEUTICALS LLC
To: HORIZON PHARMA USA RHEUMATOLOGY LLC
Reel/Frame 040648/0361 →
PATENT SECURITY AGREEMENT Recorded Sep 16, 2016
From: HORIZON PHARMA RHEUMATOLOGY LLC (FORMERLY KNOWN AS CREALTA PHARMACEUTICALS LLC)
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040059/0007 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0049 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2016
From: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 037483/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2014
From: SAVIENT PHARMACEUTICALS, INC.; SAVIENT PHARMA HOLDINGS, LLC
To: CREALTA PHARMACEUTICALS LLC
Reel/Frame 032675/0936 →
SECURITY AGREEMENT Recorded Mar 4, 2014
From: CREALTA PHARMACEUTICALS LLC
To: FIFTH STREET FINANCE CORP., AS COLLATERAL AGENT
Reel/Frame 032384/0285 →
SECURITY AGREEMENT Recorded Feb 21, 2014
From: CREALTA PHARMACEUTICALS LLC
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 032319/0077 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 028363 FRAME 0040. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Jul 23, 2013
From: SAVIENT PHARMACEUTICALS, INC.
To: U.S. NATIONAL BANK ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030936/0072 →
SECURITY AGREEMENT Recorded Jun 12, 2012
From: SAVIENT PHARMACEUTICALS, INC.
To: MORGAN STANLEY SENIOR FUNDING INC.
Reel/Frame 028363/0040 →
Continuity (3)
Division 11918297
Provisional Application 60670573 · Apr 11, 2005
Related Publication 20120309085A1 · Dec 6, 2012